{
    "nct_id": "NCT06162572",
    "official_title": "A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression",
    "inclusion_criteria": "* Adult patient aged ≥ 18 years\n* Written informed consent\n* Histologically (squamous or non-squamous) or cytologically documented locally advanced NSCLC not eligible for surgical resection and/or definitive chemoradiation, or metastatic NSCLC\n* No prior systemic treatment for locally advanced or metastatic NSCLC\n* High tumor cell PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] based on documented status as determined by an approved test\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Measurable disease as determined by RECIST v1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Tumors harboring driver mutations/genetic aberrations for which targeted therapies are approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1 aberrations)\n* Prior immune checkpoint inhibitor therapy\n* Active brain metastases\n* Participants with active and uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection\n* Uncontrolled HIV infection. Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are allowed to enroll\n* Active, known or suspected autoimmune disease or immune deficiency\n* History of hypersensitivity reactions to any ingredient of the investigational medicinal product (IMP) and other monoclonal antibody (mAbs) and/or their excipients\n* History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis ≥ grade 2\n* History of inflammatory bowel disease or colitis ≥ grade 2\n* History of hemophagocytic lymphohistiocytosis.\n* Systemic chronic steroid therapy (>10mg/d prednisone or equivalent)\n* Active infection, including infection requiring systemic antibiotic therapy\n* Pregnant or breast-feeding (lactating) women\n* Participants with a history of allogeneic organ transplantation (e.g., stem cell or solid organ transplant)\n* Any medical condition that would in the investigator's judgement prevent the participant's participation in the clinical study",
    "miscellaneous_criteria": ""
}